A live and archived webcast of the event will be available on the “Investors” section of the Certara website at About Certara Certara accelerates medicines using biosimulation software, technology ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a ...

Princeton-based Certara, announced the launch of Hasharc, its decentralized application (DApp) for health care, built in conjunction with the Hedera public Distributed Ledger Technology (DLT). Hasharc ...

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. Certara ...

Certara, Inc. provides biosimulation software and services to the biotech and biopharma industry. The company is enjoying sales growth from its software division in the mid-teen but service growth is ...

Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of ...

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...

Princeton-based Certara, a drug development, regulatory science, real-world evidence and market access services company, announced on Wednesday four senior executive appointments in its Simcyp ...

Certara, Inc. will announce Q2 2025 financial results on August 6, 2025, with a conference call at 5:00 PM ET. Certara, Inc. announced it will release its second-quarter financial results for 2025 on ...

Investors in Certara, Inc. CERT need to pay close attention to the stock based on moves in the options market lately. That is because the Aug. 15, 2025 $2.50 Call had some of the highest implied ...

RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief ...

Also Read: What’s Going On With Charles River, Certara, Simulations Plus Stocks On Friday? Certara CEO William F. Feehery noted that the board’s recent $100 million repurchase authorization reflects ...